The conversation around CJC 1295 ipamorelin oral delivery has shifted dramatically in 2026. What was once a firmly injection-dominated research space is now seeing genuine scientific and commercial interest in CJC 1295 oral tablet formulations — driven by advances in peptide stabilization technology, growing demand for needle-free alternatives, and a research community increasingly focused on improving compliance and accessibility […]